Tuesday, 18 Dec 2018

You are here

An Association between GCA and IBD ?

A population based analysis from Israel suggests that giant cell arteritis (GCA) patients may be at increased risk for  inflammatory bowel diseases (IBD) mainly target.

This research was based on sporadic reports in the medical literature (http://bit.ly/2pnIPM0)

Claims data analysis of 3938 GCA patients and 21,623 matched controls finds that  GCA patients had a significantly increased rates of CD and UC (0.79% vs. 0.12% and 0.84% vs. 0.21%, P-value < .001, respectively) when compared to normal controls.

This GCA and IBD association was negatively correlated with the patients' age; and was more robust in middle-aged (OR = 8.13) than in elderly patients (OR = 3.81).

Such data should influence the medical and GI evaluations of GCA patients suffering from gastrointestinal complaints, especially in middle-aged patients (50-69 years of age).  Moreover, age related routine colonoscopy should be strongly encouraged in such GCA patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

The GI literature is growing with the suggestion that IL-6 is the next cytokine in Crohn's Disease. The question I have had to come to terms with is when it is seen in younger patients < 40 yo) and whether this is Takayasu's or Aortitis unique to CD. As such is this an extra-intestinal manifestation that might parallel the bowel (e.g. Type I Peripheral arthritis) or march on independent of the bowel (e.g spondylitis).
IL-6 is a potential new target but there is really very little published data on IL-6 inhibition in IBD patients. Whether large vessels vasculitis could be considered an extraintestinal manifestation is interesting but best left to an IBD expert to address - Ill see if I can get one to address this for you, me and the RheumNow audience. Thanks for these thoughtful comments. JC

More Like This

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma. 

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

Diagnosing Early Lupus from Mimics

A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. 

High CV Risk in Lupus

Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.